Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma Feb 7, 2022
Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American Feb 3, 2022
Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis Dec 16, 2021
Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program Dec 15, 2021
Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis Dec 13, 2021
Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition Dec 9, 2021
Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update Nov 3, 2021
